Share on StockTwits
 

Shares of Seattle Genetics (NASDAQ:SGEN) hit a new 52-week high on Tuesday, AR Network reports. The company traded as high as $49.45 and last traded at $47.41, with a volume of 873,055 shares trading hands. The stock had previously closed at $47.95.

A number of research firms have recently commented on SGEN. Analysts at RBC Capital raised their price target on shares of Seattle Genetics from $44.00 to $48.00 in a research note to investors on Friday, December 20th. Analysts at Piper Jaffray reiterated an “underweight” rating on shares of Seattle Genetics in a research note to investors on Monday, December 9th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $42.24.

Seattle Genetics has a 52-week low of $26.60 and a 52-week high of $49.23. The stock has a 50-day moving average of $41.28 and a 200-day moving average of $41.37. The company’s market cap is $5.873 billion.

Seattle Genetics (NASDAQ:SGEN) last announced its earnings results on Tuesday, November 5th. The company reported ($0.19) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.22) by $0.03. The company had revenue of $71.00 million for the quarter, compared to the consensus estimate of $57.79 million. During the same quarter in the prior year, the company posted ($0.12) earnings per share. The company’s quarterly revenue was up 42.5% on a year-over-year basis. Analysts expect that Seattle Genetics will post $-0.63 EPS for the current fiscal year.

Seattle Genetics, Inc is biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for cancer.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.